141 results
8-K
EX-99.1
AUPH
Aurinia Pharmaceuticals Inc
2 May 24
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
6:03am
of a label update for LUPKYNIS which now includes long-term efficacy data from our AURORA Clinical Program. We have also launched an innovative new marketing … not been established beyond one year. The label now includes long-term data from a post-hoc analysis of the AURORA 2 extension study showing
8-K
EX-99.1
3hhva
15 Feb 24
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
6:06am
8-K
EX-99.1
4sme rkcrd
2 Nov 23
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
6:01am
PX14A6G
9dkrb
6 Jul 23
Letter to shareholders
8:33am
DEFA14A
2yk71jl zzf
8 May 23
Additional proxy soliciting materials
4:04pm
DEFA14A
dv6pq09dpijv5
2 May 23
Additional proxy soliciting materials
4:39pm
PX14A6G
cqhdv
26 Apr 23
Letter to shareholders
10:20am
8-K
EX-99.1
sft5q fan0kl38fo2
5 Apr 23
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
8:16am
8-K
sqnk0ej
5 Apr 23
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
8:16am
8-K
EX-99.2
2znwrq
5 Apr 23
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
8:16am